Nuveen
ALNY icon

Nuveen’s Alnylam Pharmaceuticals ALNY Stock Holding History

Nuveen’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-31,000
Closed -$5K – 3414
2021
Q2 		$5K Buy
+31,000
New +$4.54M ﹤0.01% 3302

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen's ALNY Position: Q2 2026 in Review

Nuveen reduced its Alnylam Pharmaceuticals (ALNY) stake by 2% in Q2 2026, selling an estimated $1.99M and leaving 315,630 shares worth $95M. The position accounts for 0.02% of the portfolio, ranked #437.

Nuveen first reported a position in ALNY in Q3 2013 and has held it in 36 quarters since. The position peaked at $3.32B in Q3 2022. 793 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Nuveen held 315,630 shares of Alnylam Pharmaceuticals worth $95M as of Q2 2026.
  • Nuveen sold 6,602 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $1.99M.
  • Alnylam Pharmaceuticals made up 0.02% of Nuveen's portfolio in Q2 2026, its #437 holding.
  • Nuveen first reported a position in Alnylam Pharmaceuticals in Q3 2013 and has held it in 36 quarters since.
  • Nuveen's Alnylam Pharmaceuticals position peaked at $3.32B in Q3 2022.
  • 793 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.